Amedica has been granted marketing clearance in Australia for Valeo® silicon nitride ceramic interbody fusion devices.
Leadership notes that, in 1986-1988, Australian surgeons and engineers were the first to synthesize reaction-bonded silicon nitride and implant the material in lumbar spine fusion patients. Favorable outcomes were reported at 15-year follow-up.
In the U.S., at the end of 2016, the company re-filed an application with FDA for a modified cancellous-structured ceramic (CsC)-based cervical implant that is comparable to the Valeo C cervical implant.
Amedica has been granted marketing clearance in Australia for Valeo® silicon nitride ceramic interbody fusion devices.
Leadership notes that, in 1986-1988, Australian surgeons and engineers were the first to synthesize reaction-bonded silicon nitride and implant the material in lumbar spine fusion patients. Favorable outcomes were reported...
Amedica has been granted marketing clearance in Australia for Valeo® silicon nitride ceramic interbody fusion devices.
Leadership notes that, in 1986-1988, Australian surgeons and engineers were the first to synthesize reaction-bonded silicon nitride and implant the material in lumbar spine fusion patients. Favorable outcomes were reported at 15-year follow-up.
In the U.S., at the end of 2016, the company re-filed an application with FDA for a modified cancellous-structured ceramic (CsC)-based cervical implant that is comparable to the Valeo C cervical implant.
Copy to clipboard 
